SUPT4H1-edited stem cell therapy rescues neuronal dysfunction in a mouse model for Huntington's disease

Area of Science:

• Neuroscience
• Genetics
• Stem Cell Biology

Background:

• Huntington's disease (HD) is an inherited neurodegenerative disorder caused by CAG repeat expansion in the huntingtin gene (HTT).
• Current treatments for HD are limited, with no available cure.
• Gene silencing strategies and stem cell therapies show promise but face challenges with autologous cell transplantation due to mutant HTT expression.

Purpose of the Study:

• To investigate the therapeutic potential of ex vivo SUPT4H1 gene editing in Huntington's disease stem cells.
• To determine if SUPT4H1 editing can reduce mutant huntingtin (mHTT) expression and improve cell differentiation for transplantation.

Main Methods:

• Targeted gene editing of the SUPT4H1 gene in Huntington's disease-induced pluripotent stem cell-derived neural precursor cells (iPSC-NPCs).
• Transplantation of SUPT4H1-edited and unedited HD iPSC-NPCs into YAC128 transgenic mouse model of Huntington's disease.
• Assessment of motor function, mutant HTT levels, and neuronal/astrocyte differentiation via immunohistochemistry.

Main Results:

• SUPT4H1-edited HD iPSC-NPC transplantation improved motor function in YAC128 mice compared to unedited cells.
• Immunohistochemistry confirmed reduced mutant HTT expression without affecting wild-type HTT levels.
• SUPT4H1 editing promoted neuronal differentiation and reduced reactive astrocyte differentiation in HD iPSC-NPCs.

Conclusions:

• Ex vivo editing of SUPT4H1 represents a viable strategy to reduce mutant HTT expression in patient-derived stem cells.
• SUPT4H1 gene editing enhances the therapeutic potential of autologous stem cell transplantation for Huntington's disease by improving cell quality and function.